Jul 26, 2023
In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI.
Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-SMI
Learning Objectives: After completing this educational activity, you should be better able to:
Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was planned by and for the healthcare team, and
learners will receive 1.0 Interprofessional Continuing Education
(IPCE) credit for learning and change.
A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity does not pertain to pharmacology and is worth 0.0 continuing education hour of pharmacotherapeutics.
Credit Types: The following are being offered for this activity:
Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented.
Interviewer
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY
Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad,
CA
Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome,
Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium,
Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora,
Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion,
Supernus, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium,
Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine,
Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma
Interviewees
Stephen M. Stahl, MD, PhD, DSc (Hon.)
Clinical Professor, Department of Psychiatry and Neuroscience,
University of California, Riverside School of Medicine, Riverside,
CA
Adjunct Professor, Department of Psychiatry, University of
California, San Diego School of Medicine, La Jolla, CA
Honorary Visiting Senior Fellow, University of Cambridge,
Cambridge, UK
Editor-in-Chief, CNS Spectrums
Director of Psychopharmacology Services, California Department
of State Hospitals
Grant/Research: Acadia, Alkermes, Allergan/AbbVie, Arbor, AssureX,
AstraZeneca, Avanir, Axovant, Biogen, Boehringer Ingelheim
Braeburn, BristolMyer Squibb, Celgene, CeNeRex, Cephalon, Daiichi
Sankyo-Brazil, Dey, Eisai, Forest, Genomind, Glaxo Smith Kline,
Harmony Biosciences, Indivior, Intra-Cellular, Ironshore, Janssen,
JayMac, Jazz, Lilly, Lundbeck, Merck, Neurocrine, Neuronetics,
Novartis, Otsuka, Pear, Pfizer, Reviva, Roche, Sage, Servier,
Shire, Sprout, Sunovion, Supernus, Takeda, Teva, Tonix, Torrent,
Vanda
Consultant/Advisor: Acadia, Adamas, Alkermes, Allergan/AbbVie,
Altus, Arbor, AstraZeneca, Avanir, Axovant, Axsome, Biogen,
Biomarin, Biopharma, Celgene, Cerevel, ClearView, Clexio, Concert,
DepotMed, Done, EMD Serono, Eisai, Enveric, Eurolink, Fabre-Kramer,
Ferring, Forest, Gedeon Richter, Genetica, Genomind, Innovative
Science Solutions, Impel, Intra-Cellular, Ironshore, Janssen, Jazz,
Karuna, Libbs, Lilly, Lipidio, Longboard, Lundbeck, Merck, Neos,
NeuraWell, Neurocrine, NeuroPharma, Novartis, Noveida, Otsuka,
Perrigo, Pfizer, Pierre Fabre, Proxymm, Recordati, Relmada, Reviva,
Sage, Saniona, Servier, Shire, Sprout, Sunovion, Supernus, Takeda,
Taliaz, Teva, Tonix, Tris, Trius, Vanda, Vertex, Viforpharma
Speakers Bureau: Acadia, Allergan/AbbVie, Genentech, Janssen,
Lundbeck, Merck, Neurocrine, Otsuka, Servier, Sunovion, Takeda,
Teva
Options Holdings: Delix, Genomind, Lipidio, NeuraWell
Sarah Y. Vinson, MD,
FAPA
Interim Department Chair; Clinical Associate Professor;
Director, Child and Adolescent Psychiatry Fellowship Program;
Department of Psychiatry and Behavioral Sciences, Morehouse School
of Medicine, Atlanta, GA
Medical Director, Substance Abuse and Mental Health Services
Administration (SAMHSA) African American Behavioral Health Center
of Excellence, Atlanta, GA
No financial relationships to disclose.
Pre-Interview
Author
Sabrina K. Bradbury-Segal, PhD
Senior Medical Writer, Neuroscience Education Institute,
Carlsbad, CA
No financial relationships to disclose.
The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.
Support: This activity is supported by an unrestricted educational grant from Alkermes.
Released: July 25, 2023 CME/CE credit expires: July 24, 2026